Search clinical trials for: AZD8566

Total 77 results

AstraZeneca

Completed

AZD8566 Food Effect/Microtracer Study

Healthy Volunteer Study

United Kingdom
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.

Healthy Volunteer

United Kingdom
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.

Pharmacokinetics

United Kingdom
AstraZeneca

Completed

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Schizophrenia

United States
AstraZeneca

Completed

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Reflux

Netherlands, Belgium
Dizal Pharmaceuticals

Not yet recruiting

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

Australia
AstraZeneca

Completed

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes (MAD)

Type 2 Diabetes

United States
AstraZeneca

Terminated

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Lymphoma | Multiple Myeloma | Advanced Solid Tumors | Hematologic Malignancies

United States
AstraZeneca

Completed

To Evaluate the Bioavailability of a Tablet of AZD1656

Type 1 Diabetes

United States
AstraZeneca

Completed

An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516

Healthy

Sweden
AstraZeneca

Completed

Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM) (ADME)

Type II Diabetes Mellitus

United States
Dizal Pharmaceuticals

Recruiting

A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

China
AstraZeneca

Completed

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

Glucose Lowering

United States
AstraZeneca

Completed

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

Healthy Volunteers

United States
Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Completed

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

Lymphoma, Non-Hodgkin

United States
Queen Mary University of London
AstraZeneca

Active, not recruiting

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce (ADOPTION)

Diabetes Mellitus, Type 2 | End Stage Renal Disease | Type 2 Diabetes | Renal Transplant | Kidney Transplant; Complications

United Kingdom
AstraZeneca

Completed

AZD8529 Multiple Ascending Dose Study in Healthy Subjects

Healthy Volunteer
St George Street Capital

Completed

AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (ARCADIA)

Covid19

Czechia, Romania, United Kingdom
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects

Healthy

Japan
AstraZeneca

Completed

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients (JMAD)

Type 2 Diabetes

Japan
AstraZeneca

Completed

AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects (JSAD)

Healthy

United Kingdom
AstraZeneca

Completed

Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Japan
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

Type 2 Diabetes Mellitus

United States
AstraZeneca
Quintiles, Inc.

Completed

To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers

Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years. | Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80

United Kingdom
AstraZeneca

Completed

AZD8529 Single Ascending Dose Study (SAD)

Healthy Volunteer

United States
National Institute on Drug Abuse (NIDA)

Completed

The Study of AZD8529 for Smoking Cessation in Female Smokers

Tobacco Use Disorder

United States
AlzeCure Pharma

Completed

Study Evaluating the Pharmacokinetics of a Single Microdose of ACD856

Alzheimer Disease | Cognition Disorder

Sweden
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 (PET)

Healthy

Sweden
AstraZeneca

Completed

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

Healthy | Memory Impairment

United States
AlzeCure Pharma

Completed

Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics

Alzheimer Disease | Cognition Disorder

Sweden
AstraZeneca

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Adenocarcinoma | Gastro-esophageal Junction Cancer

Korea, Republic of, United States, Japan, Taiwan, China, United Kingdom, Netherlands
AstraZeneca

Terminated

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

Thrombin Inhibition

United States
AstraZeneca

Completed

AZD8186 First Time In Patient Ascending Dose Study

Advanced Castrate-resistant Prostate Cancer CRPC | Squamous Non-Small Cell Lung Cancer sqNSCLC | Triple Negative Breast Cancer TNBC

Spain, Canada, United States, United Kingdom
AstraZeneca

Completed

Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

Pain

United Kingdom
AstraZeneca

Terminated

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Spain, United States, Korea, Republic of, France, Portugal, Australia, Italy
AstraZeneca

Completed

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

Pain | Diabetic Neuropathy

United States
AstraZeneca

Completed

To Evaluate 24-hr Glucose After OD vs BD AZD1656

Type II Diabetes

United States
AstraZeneca
Quintiles, Inc.

Terminated

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity (NP-MH)

Neuropathic Pain | Mechanical Hypersensitivity

United States
AstraZeneca

Completed

AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers

Healthy
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

Rheumatoid Arthritis

Germany, United Kingdom
AstraZeneca

Completed

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

Type II Diabetes

United States
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects

Pain

Sweden
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers

Healthy

Sweden
AstraZeneca

Completed

14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations

Reflux Episodes

Netherlands
AstraZeneca

Completed

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

Type 2 Diabetes

United States, India
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects

Healthy

Japan
AstraZeneca

Completed

Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Type 2 Diabetes

United States
AstraZeneca

Completed

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

Type 2 Diabetes

United States
AstraZeneca

Completed

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

Type II Diabetes Mellitus

United States

3

Subscribe